Introduction
Prostatic biopsy under transrectal ultrasound (TRUS) guidance is a procedure of choice in the tissue diagnosis of prostatic carcinoma. 1 It is very well established that urologists or uroradiologists can easily perfom this method with very limited morbidity in the outpatient setting. 2, 3 From the patients' perspective, prostatic biopsy can be easily tolerated if effective pain management is undertaken. Various types of anesthesia methods have been tested in different studies in order to define the best method for TRUS-guided prostatic biopsy. Soloway and Obek 4 demonstrated, in a nonrandomized study, that periprostatic lidocaine injection is a very effective form of anesthesia for prostate biopsy. This suggestion has been reinforced by Leibovici et al, 5 who performed a double-blind randomized placebocontrolled study and determined that lidocaine injection is an effective method of anesthesia for prostate biopsy. We recently reported our results regarding the effect of intrarectal lidocaine instillation in the pain management of prostatic biopsy in which we failed to show any benefit from this form of anesthesia. 6 Here in this study, we evaluated the benefit of intrarectal lidocaine injection anesthesia in patients undergoing TRUS-guided prostate biopsy.
Patients and methods
Patients admitted to our outpatient clinic were evaluated for inclusion into this study. Prostate biopsy was indicated in patients with elevated total prostate-specific antigen (tPSA) and/or abnormal digital rectal examination (DRE). Exclusion criteria were a history of transrectal prostate biopsy, anal fissure or stricture, any neurological sequelae or concomitant use of pain medicine. The first patient was enrolled in August 1999 and the study was terminated in October 2002 upon the inclusion of the 100th eligible patient.
Utilizing a second group (placebo) of 50 patients as a control, we applied transrectal lidocaine injection anesthesia on another 50 patients, to evaluate the efficacy of this route. Thus, patients were evaluated in two groups: group I received a total of 10 cm 3 (5 cm 3 on each side) of 1% lidocaine solution injected (utilizing the outer sheath of 18G tru-cut needle) transrectally through the ultrasound probe at the prostato-seminalvesicular junction 10 min before TRUS-guided prostate biopsy, and group II (the placebo group) received 20 cm 3 of intrarectal serum physiologic instillation.
Groups were not different from each other with respect to patient age, mean tPSA and mean biopsy time (Table 1) . Biopsy time was measured as the time period elapsed between the first biopsy core and the last one. Antibiotic prophylaxis with 1 g ceftriaxone was given 30 min before biopsy and was continued with 400 mg of ofloxacine q.d. for 2 days.
Biopsy was performed in the clinic with the patient in the left lateral decubitus position. All biopsies were performed using a B&K Panther 2002 ultrasound scanner with an endosonic multiplane 7.5 MHz transducer, and biopsies were taken using an automatic spring-loaded 18 G needle. A total of 12 biopsies were obtained from all patients. These were obtained with the prostate imaged in the sagittal plane with a systematic approach; three specimens were taken from the base, mid-gland and apex of the right and left sides of the prostate in the peripheral zone, and the same amount of biopsies was also taken more laterally to the initial six biopsies. Cores were labeled according to the location from which they were obtained (base, mid, apex) on each side and sent for pathological analysis. All patients were monitored for approximately 15 min after the procedure, during which they graded the level of discomfort and/or pain from the procedure on a 10-point modified visual analog scale (VAS). Pain perception was rated (Verbal Rating Score modification) by utilizing VAS scores as no pain (VAS ¼ 0-2), and mild (VAS ¼ 3, 4), moderate (VAS ¼ 5, 6), severe (VAS ¼ 7, 8) and intolerable pain (VAS ¼ 9, 10). 6 Following the procedure, the patients were followed within the perioperative period (1 month) for the evaluation of complications. Patients were observed and questioned for the presence of rectal bleeding, hematuria, urinary retention, vaso-vagal episodes, fever, hematospermia and urinary tract infection during this period.
Statistical analyses were performed by utilizing a computerized software package (STATA statistical package, College Station, TX, USA). Categorical variables among groups were analyzed by w 2 test. Student's t-test was used to compare continuous variables between two groups. Continuous and ordinal variables among more than two groups were analyzed with Kruskal-Wallis test.
Results
During the study period, 100 patients were enrolled in the study: 50 patients were enrolled in group I and 50 patients in group II. Table 2 shows pathology results and mean VAS pain scores. Note that prostate cancer (CaP) and benign pathology are mutually exclusive pathologic categories. Mean pain VAS score was statistically significantly better (P ¼ 0.0001) in the lidocaine injection group (group I). Furthermore, no patient had a VAS pain score 5 in this group. Although most of the patients in the control group (group II) experienced mild to moderate pain, none of the patients in group I had a VAS pain score worse than the mild category. While severe to intolerable pain was not experienced in any patient in group I, 16% of the patients in group II reported this magnitude of pain perception (Po0.0001).
Results are summarized with respect to different age categories in groups I and II (Tables 3 and 4) . Although there was no statistically significant difference in group II (Table 4 ) with respect to mean VAS pain score, this difference was significant in group I (Table 3) . No statistically significant difference in the number of patients with VAS 5 was observed among different age categories within group I (Table 3) or II (Table 4) . When mean VAS pain perception scores in identical age categories in group I were compared with those in group II, there was marked statistically significant difference (Table 5 ) and no patient had septicemia. When the protocol described above is carefully followed, the biopsy procedure can be performed with almost no serious untoward effect on the patients.
Discussion
Pain relief during TRUS-guided prostatic biopsy has been a very popular issue in the urologic community in recent years. Certainly every treatment or diagnostic procedure has implications with respect to quality of life. Although not universal, recently many authors favor anesthesia as a pain diminisher during prostatic biopsy. [7] [8] [9] Advances in biopsy instruments such as spring-loaded biopsy guns and ultrasound visualization have dramatically improved the ease of prostate biopsy. On the other hand, not an insignificant number of patients still find this procedure unpleasant and uncomfortable. In one study by Irani et al 10 , where no anesthesia was used, about 19% of patients reported that they would refuse to undergo rebiopsy without anesthesia again. Furthermore, 6% of the patients in this study proposed that prostate biopsy should be carried out under general anesthesia. This opinion or judgement strongly implies the necessity of analgesia to diminish pain resulting from biopsy.
This suggestion was valued and studied by some authors. Peters et al 9 conducted a study where they compared the efficacy of sedation (intravenous propofol, n ¼ 130) with patients who did not have sedation (n ¼ 100). In this study, they found significantly reduced patient discomfort and they recommended sedation anesthesia, especially for patients who need repeated prostatic biopsies. The authors also emphasized the need for cost analysis which was not considered in this study; obviously, propofol anesthesia needed operation theatre conditions increasing cost. Operating room conditions certainly create a number of unpleasant and redundant experiences on patients, which render the biopsy procedure unnecessarily complicated.
Among the many studies initiated to assess the effect of different anesthesia methods in order to define the best method of pain relief, intrarectal lidocaine gel analgesia has also been studied. Although some randomized studies reported benefit from the use of this form of application, 11 some other randomized trials, including our previous study, failed to show significant improvement in pain perception. 6, 7 The mean VAS score in patients who had lidocaine gel analgesia in our previous study was 4.70, 6 while it significantly improved to 1.46 in patients who had lidocaine injection anesthesia (group I) in the present study. This clearly showed that injection anesthesia significantly improves pain perception when compared with local gel application.
Several trials have also investigated the use of local injection anesthesia in an attempt to relieve the pain resulting from prostate biopsy.
3,5,12,13 Nash et al 8 were the first to evaluate injection anesthesia and they reported lower discomfort in the anesthetized side of the prostate compared with the unanesthetized one. In another study by Leibovici et al, 5 injection anesthesia significantly reduced the pain score from 4.15 to 3.06, as in the present study where pain score diminished more remarkably from 4.50 to 1.46 (Table 2) . Alavi et al, 13 utilizing an injection anesthesia identical to our present study, obtained a mean VAS score of 2.4 in anesthetized patients which is higher than our value (mean VAS ¼ 1.46, Table 2 ), but still within the vicinity of the 'no pain' category. Although the patients (lidocaine injection group) in our study had 8% mild and 0% moderate VAS pain scores (Fig 1) , patients in the study Figure 1 Percent distribution of pain perception in two groups: group I, lidocaine; group II, placebo. 13 In the present study, about 50% of the patients who did not receive lidocaine injection had a VAS pain score ranging from moderate to intolerable severity; 16% of these patients had severe to intolerable pain during biopsy. However, none of the anesthetized patients had a moderate to intolerable VAS pain score. In one study by Issa et al where no anesthetic agent was used as a control group, similarly, more than 50% of the patients had moderate to intolerable pain. Many randomized studies in the literature showed that patients who received nerve block had less pain and discomfort than those who did not. 5, 13 As a result of these studies, including ours, we are strongly convinced that prostate biopsy without anesthesia is certainly a more painful procedure.
The relation of pain perception with age was studied in two other studies, in addition to ours. Although the study by Djavan et al, 14 where no anesthesia was used, showed that patients younger than 60 y had significantly worse pain scores, our present study failed to show any difference in group II (placebo). In another study by Leibovici et al, 5 age did not have any influence on pain scores. Our results are not different from this study because pain scores, across all age categories, were in the ''no pain'' category. Results present in the literature so far regarding the age issue are very much conflicting; hence this requires further investigation.
As a conclusion, TRUS-guided biopsy of the prostate should be performed under periprostatic lidocaine injection anesthesia because it is significantly less painful, and not time consuming, cumbersome or costly. Furthermore, it does not require sophisticated facilities, such as an operating theater, as in sedation anesthesia.
